| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (R.R.N.); Institute de Recherches Internationales Servier, Neuilly sur Seine, France (M.S.); Systems Research, GlaxoSmithKline Research and Development, Research Triangle Park, North Carolina (T.K.); and Department of Pharmacology, University of Melbourne, Parkville, Australia (A.C.)
The recommendations that follow have been updated from the proposals of a Technical Subcommittee set up by the International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification (Jenkinson DH, Barnard EA, Hoyer D, Humphrey PPA, Leff P, and Shankley NP (1995) International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. IX. Recommendations on terms and symbols in quantitative pharmacology. Pharmacol Rev 47:255–266).
Abstract I. Introduction II. Working Definition of a Receptor III. Use of Drugs in Definition of Receptors or of Signaling Pathways A. The Expression of Amount of Drug: Concentration and Dose B. General Terms Used to Describe Drug Action C. Experimental Measures of Drug Action D. Terms and Procedures Used in the Analysis of Drug Action IV. Appendix A. Microscopic and Macroscopic Equilibrium Constants B. Schild Equation and Plot—Further Detail C. The Relationship between the Hill and Logistic Equation
This article has been cited by other articles:
|
|
 |
|
  B. Holst, T. M. Frimurer, J. Mokrosinski, T. Halkjaer, K. B. Cullberg, C. R. Underwood, and T. W. Schwartz Overlapping Binding Site for the Endogenous Agonist, Small-Molecule Agonists, and Ago-allosteric Modulators on the Ghrelin Receptor Mol. Pharmacol., January 1, 2009; 75(1): 44 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J. Harmar, R. A. Hills, E. M. Rosser, M. Jones, O. P. Buneman, D. R. Dunbar, S. D. Greenhill, V. A. Hale, J. L. Sharman, T. I. Bonner, et al. IUPHAR-DB: the IUPHAR database of G protein-coupled receptors and ion channels Nucleic Acids Res., January 1, 2009; 37(suppl_1): D680 - D685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Nicholls, N. P. Tomkinson, K. E. Wiley, A. Brammall, L. Bowers, C. Grahames, A. Gaw, P. Meghani, P. Shelton, T. J. Wright, et al. Identification of a Putative Intracellular Allosteric Antagonist Binding-Site in the CXC Chemokine Receptors 1 and 2 Mol. Pharmacol., November 1, 2008; 74(5): 1193 - 1202. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. C. Jensen, S. Thiele, T. Ulven, T. W. Schwartz, and M. M. Rosenkilde Positive Versus Negative Modulation of Different Endogenous Chemokines for CC-chemokine Receptor 1 by Small Molecule Agonists through Allosteric Versus Orthosteric Binding J. Biol. Chem., August 22, 2008; 283(34): 23121 - 23128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Roy, E. J. Halvey, and J. Garthwaite An Enzyme-linked Receptor Mechanism for Nitric Oxide-activated Guanylyl Cyclase J. Biol. Chem., July 4, 2008; 283(27): 18841 - 18851. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-P. Rospars, P. Lansky, M. Chaput, and P. Duchamp-Viret Competitive and Noncompetitive Odorant Interactions in the Early Neural Coding of Odorant Mixtures J. Neurosci., March 5, 2008; 28(10): 2659 - 2666. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Ayer, S. M. Wilson, S. L. Traves, D. Proud, and M. A. Giembycz 4,5-Dihydro-1H-imidazol-2-yl)-[4-(4-isopropoxy-benzyl)-phenyl]-amine (RO1138452) Is a Selective, Pseudo-Irreversible Orthosteric Antagonist at the Prostacyclin (IP)-Receptor Expressed by Human Airway Epithelial Cells: IP-Receptor-Mediated Inhibition of CXCL9 and CXCL10 Release J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 815 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. A. Avlani, K. J. Gregory, C. J. Morton, M. W. Parker, P. M. Sexton, and A. Christopoulos Critical Role for the Second Extracellular Loop in the Binding of Both Orthosteric and Allosteric G Protein-coupled Receptor Ligands J. Biol. Chem., August 31, 2007; 282(35): 25677 - 25686. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Spagnolo, G. Carra, M. Fantin, C. Fischetti, C. Hebbes, J. McDonald, T. A. Barnes, A. Rizzi, C. Trapella, G. Fanton, et al. J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 961 - 967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Pal, D. Mehn, E. Molnar, S. Gedey, P. Meszaros, T. Nagy, H. Glavinas, T. Janaky, O. von Richter, G. Bathori, et al. Cholesterol Potentiates ABCG2 Activity in a Heterologous Expression System: Improved in Vitro Model to Study Function of Human ABCG2 J. Pharmacol. Exp. Ther., June 1, 2007; 321(3): 1085 - 1094. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Rosenkilde, R. David, I. Oerlecke, T. Benned-Jensen, U. Geumann, A. G. Beck-Sickinger, and T. W. Schwartz Conformational Constraining of Inactive and Active States of a Seven Transmembrane Receptor by Metal Ion Site Engineering in the Extracellular End of Transmembrane Segment V Mol. Pharmacol., December 1, 2006; 70(6): 1892 - 1901. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Roth, E. Marzola, A. Rizzi, M. Arduin, C. Trapella, C. Corti, R. Vergura, P. Martinelli, S. Salvadori, D. Regoli, et al. Structure-Activity Studies on Neuropeptide S: IDENTIFICATION OF THE AMINO ACID RESIDUES CRUCIAL FOR RECEPTOR ACTIVATION J. Biol. Chem., July 28, 2006; 281(30): 20809 - 20816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. P. Fitzsimons, U. A. Gompels, D. Verzijl, H. F. Vischer, C. Mattick, R. Leurs, and M. J. Smit Chemokine-Directed Trafficking of Receptor Stimulus to Different G Proteins: Selective Inducible and Constitutive Signaling by Human Herpesvirus 6-Encoded Chemokine Receptor U51 Mol. Pharmacol., March 1, 2006; 69(3): 888 - 898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. R. Price, G. L. Baillie, A. Thomas, L. A. Stevenson, M. Easson, R. Goodwin, A. McLean, L. McIntosh, G. Goodwin, G. Walker, et al. Allosteric Modulation of the Cannabinoid CB1 Receptor Mol. Pharmacol., November 1, 2005; 68(5): 1484 - 1495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Corradetti, B. Mlinar, C. Falsini, A. M. Pugliese, A. Cilia, C. Destefani, and R. Testa Differential Effects of the 5-Hydroxytryptamine (5-HT)1A Receptor Inverse Agonists Rec 27/0224 and Rec 27/0074 on Electrophysiological Responses to 5-HT1A Receptor Activation in Rat Dorsal Raphe Nucleus and Hippocampus in Vitro J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 109 - 117. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Ballestero, P. V. Plazas, S. Kracun, M. E. Gomez-Casati, J. Taranda, C. V. Rothlin, E. Katz, N. S. Millar, and A. B. Elgoyhen Effects of Quinine, Quinidine, and Chloroquine on {alpha}9{alpha}10 Nicotinic Cholinergic Receptors Mol. Pharmacol., September 1, 2005; 68(3): 822 - 829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Bodenstein, D. P. Venter, and C. B. Brink Phenoxybenzamine and Benextramine, but Not 4-Diphenylacetoxy-N-[2-chloroethyl]piperidine Hydrochloride, Display Irreversible Noncompetitive Antagonism at G Protein-Coupled Receptors J. Pharmacol. Exp. Ther., August 1, 2005; 314(2): 891 - 905. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. T. May, Y. Lin, P. M. Sexton, and A. Christopoulos Regulation of M2 Muscarinic Acetylcholine Receptor Expression and Signaling by Prolonged Exposure to Allosteric Modulators J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 382 - 390. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
 |
 |
 |
|
 |
 |
 |
